Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia
Neoadjuvant Endocrine Therapy for pre- and postmenopausal women with T4 Nany or TanyN2-3 estrogen receptor (ER) -positive, progrsteron receptor (PR) -positive and HER2 negative breast cancer. Real Clinical Practice in Russia.
Breast Cancer|Neoadjuvant Endocrine Therapy
DRUG: Tamoxifen 20mg|DRUG: Anastrozole 1mg|DRUG: Letrozole 2.5mg|DRUG: Goserelin|DRUG: Triptorelin
the number of patients with a Residual Cancer Burden (RCB) 0-I index as a measure of efficacy, Residual cancer burden (RCB) is estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after the completion of neoadjuvant therapy. 6 variables are included in a calculation formula., Up to 5 years
clinical response in each treatment arm as defined by clinical and ultrasound examination., Up to 5 years|Preoperative Endocrine Prognostic Index (PEPI), the preoperative endocrine prognostic index (PEPI)- consisting of the pathological tumor size, pathological node status, Ki67 labeling index, and ER status of residual tumors after NAE, Up to 5 years|the rates of breast conservation therapy with regard to the initially planned surgery, Up to 5 years|Disease-free survival (DFS), DFS event is defined as the evidence of local and/or distant recurrence, new primary breast tumour, or death from any cause., Up to 5 years
Neoadjuvant Endocrine Therapy for pre- and postmenopausal women with T4 Nany or TanyN2-3 estrogen receptor (ER) -positive, progrsteron receptor (PR) -positive and HER2 negative breast cancer. Real Clinical Practice in Russia.

Nonrandomized, retrospective clincal trial

Eligible postmenopausal women were treated with tamoxifen 20 mg, exemestane 25 mg daily, letrozole 2.5 mg daily, or anastrozole 1 mg daily before surgery

or

Eligible premenopausal women were treated with tamoxifen 20 mg, exemestane 25 mg daily, letrozole 2.5 mg daily, or anastrozole 1 mg daily in combination with ovarian suppression before surgery